Vicore Pharma Holding Stock Fundamentals
| VICO Stock | SEK 7.84 0.36 4.39% |
Vicore Pharma Holding fundamentals help investors to digest information that contributes to Vicore Pharma's financial success or failures. It also enables traders to predict the movement of Vicore Stock. The fundamental analysis module provides a way to measure Vicore Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Vicore Pharma stock.
Vicore |
Vicore Pharma Holding Company Return On Equity Analysis
Vicore Pharma's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Vicore Pharma Return On Equity | -0.99 |
Most of Vicore Pharma's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Vicore Pharma Holding is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, Vicore Pharma Holding has a Return On Equity of -0.9886. This is 95.88% lower than that of the Healthcare sector and 97.29% lower than that of the Biotechnology industry. The return on equity for all Sweden stocks is notably higher than that of the company.
Vicore Pharma Holding Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Vicore Pharma's current stock value. Our valuation model uses many indicators to compare Vicore Pharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Vicore Pharma competition to find correlations between indicators driving Vicore Pharma's intrinsic value. More Info.Vicore Pharma Holding is rated first in return on equity category among its peers. It is rated first in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Vicore Pharma's earnings, one of the primary drivers of an investment's value.Vicore Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Vicore Pharma's direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Vicore Pharma could also be used in its relative valuation, which is a method of valuing Vicore Pharma by comparing valuation metrics of similar companies.Vicore Pharma is currently under evaluation in return on equity category among its peers.
Vicore Fundamentals
| Return On Equity | -0.99 | |||
| Return On Asset | -0.49 | |||
| Current Valuation | 1.22 B | |||
| Shares Outstanding | 81.85 M | |||
| Shares Owned By Insiders | 16.14 % | |||
| Shares Owned By Institutions | 51.89 % | |||
| Price To Earning | 163.82 X | |||
| Price To Book | 8.67 X | |||
| EBITDA | (293.13 M) | |||
| Net Income | (296.48 M) | |||
| Cash And Equivalents | 215.97 M | |||
| Cash Per Share | 5.10 X | |||
| Total Debt | 320 K | |||
| Current Ratio | 19.83 X | |||
| Book Value Per Share | 2.24 X | |||
| Cash Flow From Operations | (265.17 M) | |||
| Earnings Per Share | (4.76) X | |||
| Target Price | 69.6 | |||
| Number Of Employees | 23 | |||
| Beta | 0.59 | |||
| Market Capitalization | 1.26 B | |||
| Total Asset | 451.17 M | |||
| Net Asset | 451.17 M |
About Vicore Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Vicore Pharma Holding's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Vicore Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Vicore Pharma Holding based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Vicore Pharma Holding AB , through its subsidiaries, operates as a biotech company. Vicore Pharma Holding AB was founded in 2000 and is based in Mlndal, Sweden. Vicore Pharma is traded on Stockholm Stock Exchange in Sweden.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Vicore Stock Analysis
When running Vicore Pharma's price analysis, check to measure Vicore Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vicore Pharma is operating at the current time. Most of Vicore Pharma's value examination focuses on studying past and present price action to predict the probability of Vicore Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vicore Pharma's price. Additionally, you may evaluate how the addition of Vicore Pharma to your portfolios can decrease your overall portfolio volatility.